Bioreducible Carboxymethyl Dextran Nanoparticles for Tumor‐Targeted Drug Delivery
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Bioreducible carboxymethyl dextran (CMD) derivatives are synthesized by the chemical modification of CMD with lithocholic acid (LCA) through a disulfide linkage. The hydrophobic nature of LCA allows the conjugates (CMD‐SS‐LCAs) to form self‐assembled nanoparticles in aqueous conditions. Depending on the degree of LCA substitution, the particle diameters range from 163 to 242 nm. Doxorubicin (DOX), chosen as a model anticancer drug, is effectively encapsulated into the nanoparticles with high loading efficiency (>70%). In vitro optical imaging tests reveal that the fluorescence signal of DOX quenched in the bioreducible nanoparticles is highly recovered in the presence of glutathione (GSH), a tripeptide capable of reducing disulfide bonds in the intracellular compartments. Bioreducible nanoparticles rapidly release DOX when they are incubated with 10 m m GSH, whereas the drug release is greatly retarded in physiological buffer (pH 7.4). DOX‐loaded bioreducible nanoparticles exhibit higher toxicity to SCC7 cancer cells than DOX‐loaded nanoparticles without the disulfide bond. Confocal laser scanning microscopy observation demonstrate that bioreducible nanoparticles can effectively deliver DOX into the nuclei of SCC7 cells. In vivo biodistribution study indicates that Cy5.5‐labeled CMD‐SS‐LCAs selectively accumulate at tumor sites after systemic administration into tumor‐bearing mice. Notably, DOX‐loaded bioreducible nanoparticles exhibit higher antitumor efficacy than reduction‐insensitive control nanoparticles. Overall, it is evident that bioreducible CMD‐SS‐LCA nanoparticles are useful as a drug carrier for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Bae, Y., Fukushima, S., Harada, A., & Kataoka, K. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200250653 · Cited by 1,329
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382
Thambi, T., Yoon, H. Y., Kim, K., Kwon, I. C., Yoo, C. K., & Park, J. H. (2011) · Bioconjugate Chemistry · doi:10.1021/bc2000963 · Cited by 138
Self-citation
Cited by
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Multifunctional biomolecule nanostructures for cancer therapy
Wang, J., Li, Y., & Nie, G. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00315-x · Cited by 488
Polysaccharide-based nanoparticles for theranostic nanomedicine
Swierczewska, M., Han, H. S., Kim, K., Park, J. H., & Lee, S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.015 · Cited by 415
Self-citationPark, J., Choi, Y., Chang, H., Um, W., Ryu, J. H., & Kwon, I. C. (2019) · Theranostics · doi:10.7150/thno.37198 · Cited by 382
Self-citationROS-generating TiO2 nanoparticles for non-invasive sonodynamic therapy of cancer
You, D. G., Deepagan, V. G., Um, W., Jeon, S., Son, S., Chang, H., Yoon, H. I., Cho, Y. W., Swierczewska, M., Lee, S., et al. (2016) · Scientific Reports · doi:10.1038/srep23200 · Cited by 327
Self-citation
Metadata
- Authors
- Thambi, T., You, D. G., Han, H. S., Deepagan, V. G., Jeon, S. M., Suh, Y. D., Choi, K. Y., Kim, K., Kwon, I. C., Yi, G., Lee, J. Y., Lee, D. S., & Park, J. H.
- Venue
- Advanced Healthcare Materials
- Publisher
- Wiley
- Published
- 2014-04-17
- Volume
- 3
- Issue
- 11
- Pages
- 1829-1838
- ISSN
- 2192-2640 (ISSN-L)
- 2192-2659
- OpenAlex
- W2037113100
- Cited by
- 120
- References
- 5
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.